Merck to divest biosimilars arm to Fresenius Kabi

28-04-2017

Merck to divest biosimilars arm to Fresenius Kabi

sprng23 / iStockphoto.com

Merck will divest its biosimilars business to Fresenius Kabi in order to focus on innovative drugs.


Merck, Fresenius Kabi, biosimilars, m&a, biologics, innovation

LSIPR